Search

Agios Pharmaceuticals Inc

Abierto

SectorSanidad

33.39 -0.12

Resumen

Variación precio

24h

Actual

Mínimo

32.22

Máximo

33.83

Métricas clave

By Trading Economics

Ingresos

-1.6M

-101M

Ventas

24M

45M

BPA

-1.69

Margen de beneficios

-225.06

Empleados

539

EBITDA

-11M

-109M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+23.48% upside

Dividendos

By Acuity

Próximas Ganancias

29 oct 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-253M

1.9B

Apertura anterior

33.51

Cierre anterior

33.39

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

104 / 340 Clasificación en Healthcare

Agios Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ago 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher today amid unusually high trading volume. The stock has gained significantly since Tuesday's close.

11 ago 2026, 19:26 UTC

Agios Pharmaceuticals Inc shares are higher today, with no specific news driving the move. Market focus remains on upcoming U.S. inflation reports.

10 ago 2026, 21:01 UTC

Agios Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

6 ago 2026, 19:32 UTC

Agios Pharmaceuticals shares are higher today, continuing an upward trend since Wednesday. The stock peaked earlier in the session before a slight pullback.

5 ago 2026, 19:56 UTC

News

Agios Pharmaceuticals is under investigation regarding its decision on tebapivat, contributing to lower trading activity today amid ongoing investor concerns.

4 ago 2026, 20:02 UTC

Agios Pharmaceuticals Inc shares are higher today amid broader market gains, supported by falling crude oil prices and comments on potential peace talks with Iran.

3 ago 2026, 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31 jul 2026, 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30 jul 2026, 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29 jul 2026, 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28 jul 2026, 20:02 UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27 jul 2026, 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24 jul 2026, 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22 jul 2026, 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21 jul 2026, 19:01 UTC

News
Event
Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Comparación entre iguales

Cambio de precio

Agios Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

23.48% repunte

Estimación a 12 Meses

Media 41.33 USD  23.48%

Máximo 55 USD

Mínimo 31 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Agios Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

9 ratings

6

Comprar

3

Mantener

0

Vender

Sentimiento

By Acuity

104 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat